Kountourakis Panteleimon, Ajani Jaffer A, Davila Marta, Lee Jeffrey H, Bhutani Manoop S, Izzo Julie G
Gastrointest Cancer Res. 2012 Mar;5(2):49-57.
Despite advances in diagnosis and therapy, esophageal cancer remains a highly lethal disease. The incidence of esophageal adenocarcinoma (EAC) has risen faster than that of any other cancer in the western world, and Barrett's esophagus (BE) may be a significant contributing factor. In-depth knowledge of biology of cancer progression and cancer could lead to the identification of biomarkers that are the hallmark of BE's progression. By integrating validated biomarkers of progression into clinical practice, there is a possibility of identifying high-risk patient population for targeted surveillance, and such biomarkers may serve as novel therapeutic targets for chemoprevention and therapy. Clinical management of BE has improved considerably due to the improvements in endoscopic resection and ablation techniques. We discuss the current status of biology and therapeutic approaches to BE.
尽管在诊断和治疗方面取得了进展，但食管癌仍然是一种高致死性疾病。在西方世界，食管腺癌（EAC）的发病率增长速度超过了其他任何癌症，而巴雷特食管（BE）可能是一个重要的促成因素。深入了解癌症进展和癌症生物学知识可能会导致识别出作为BE进展标志的生物标志物。通过将经过验证的进展生物标志物整合到临床实践中，有可能识别出需要进行靶向监测的高危患者群体，并且这些生物标志物可能成为化学预防和治疗的新型治疗靶点。由于内镜切除和消融技术的改进，BE的临床管理有了显著改善。我们讨论了BE的生物学现状和治疗方法。
